A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

Taiwan

Department of Oncology, National Taiwan University Hospital, Taipei

Department of Oncology,National Taiwan University Hospital, Taipei